IRLAB has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2b trial for its investigational medication, pirepemat (previously known as IRL752), which is intended to treat impaired balance and prevent falls in patients with Parkinson’s disease. “Pirepemat has potential to be the first…
News
According to an online survey, the COVID-19 pandemic negatively affected the caregivers of patients with Parkinson’s disease, with a large proportion of caregivers reporting feeling sadness and anxiety. The findings of the study, “COVID-19’s Impact on Burden and Nutrition for Family Caregivers of People With Parkinson’s Disease,”…
In Parkinson’s patients, greater nerve damage in the skin around the ankle is significantly associated with subsequent progression of motor symptoms, while the presence of such damage in neck skin is linked to progressive cognitive decline, a study shows. Notably, this nerve damage progression was not related to increased…
A commonly used measure of how motor symptoms are affecting daily life could also — for people in early stages of Parkinson’s disease — be taking into account the contribution of their non-motor symptoms, a study suggests. This is a likely reason for the discrepancies seen in evaluations made by patients…
Researchers have developed a highly-sensitive alpha-synuclein-based test that accurately distinguishes people with Parkinson’s from those without the disease and those with other alpha-synucleinopathies, which sometimes are difficult to distinguish based on symptoms alone. The test also was able to predict the future conversion to Parkinson’s among people with…
Argobio and GeneCode are teaming up to develop small molecules mimicking glial cell-derived neurotrophic factor (GDNF), a protein that helps nerve cells survive, for the treatment of Parkinson’s and other diseases. The collaboration builds on previous work by researchers at GeneCode, who together with Mart Saarma, PhD,…
Parkinson’s-related mutations in the LRRK2 gene, in the presence of pro-inflammatory stimuli, affect the uptake and trafficking of iron in brain cells, leading to its abnormal accumulation and “mislocalization.” That’s according to a new study in mouse models and cells derived from Parkinson’s patients, which demonstrates “altered regulation of…
The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded about $1.5 million in grants to AC Immune to support work into small molecules against two proteins that are key players in the neurodegeneration underlying Parkinson’s disease. The two grants will fund research into molecules able to enter the brain…
The use of several Parkinson’s disease medications was significantly associated with the increased abundance of a bacterial enzyme that converts levodopa to dopamine in the gut, potentially reducing levodopa’s availability in the brain, a study found. In Parkinson’s patients with rapidly progressing disease, the approved therapy Comtan (entacapone)…
No significant correlation was found between the consumption of well water and the risk of developing Parkinson’s disease, according to the results of a pooled analysis of multiple studies. However, there was a high degree of variability — what scientists call heterogeneity — between the selected studies, with some…
Recent Posts
- FDA grants advanced therapy status to Parkinson’s cell treatment
- Experimental drug BT-267 shows promise in Parkinson’s study
- Saying goodbye to my doctors leaves me sad, but grateful
- Deep brain stimulation was a lifesaver for my husband with Parkinson’s
- Me and Mary Jane: My one experience trying marijuana for Parkinson’s